Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 October 2019 | Story Eugene Seegers | Photo Charl Devenish
Pieter Hoogenboezem
Pieter Hoogenboezem with his proud parents, dad Hans and mom Eldi, and Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.


Photo Gallery

At a gala event held on the University of the Free State (UFS) Bloemfontein Campus, on 28 September 2019, the top 14 entrants in the 39th UFS-Volksblad Matriculant of the Year competition were given an opportunity to share their vision with invited guests.

In his introductory speech, Pieter Hoogenboezem, deputy head boy of Pietersburg High School in Polokwane, Limpopo, said: “I think the Matriculant of the Year should strive to do their best in everything they attempt, and they should be good at communicating with others.” Pieter will be studying medicine at the UFS next year. He was crowned the winner of the 2019 Matriculant of the Year competition and also received the Sparkling Personality award, as decided by his fellow finalists. 

Pieter says of this achievement: “I am humbled and so blessed with the talents my heavenly Father has given me. I believe that the training and knowledge that I will receive at the UFS will empower me to make a worthwhile contribution to the medical field and society at large. It is going to be a great privilege for me to make Kovsies proud and to move others to become part of this university that promotes transformation, diversity, and inclusivity!”

Several other prizes were also awarded during the evening. Mandie de Wet from the Hoër Meisieskool Oranje in Bloemfontein walked away with the prize for best achievement in sport for her prowess on the hockey field, and Runé Edeling (Eunice High School) was rewarded for her accomplishments in dressage on a national level, as well as her extensive scientific knowledge and ability shown at the Eskom Expo, the Eskom Science Fair, and an international science expo in Arizona, USA. Each of these winners received R5 000 from the Kovsie Alumni Trust.

Dr Pieter Rademan, Matriculant of the Year 2009, had this to say to the finalists — many of whom will start studying next year to become doctors: “I’m delighted to see that so many here are interested in medicine; there is a desperate need for more doctors and good doctors in the country.” Using an example from the Norsemen, he told the matriculants: “Despite being shipbuilders and seafarers, the Vikings would set fire to their ships when they reached their destination.” He said this ensured that they would be motivated to overcome difficulties before rebuilding their vessels to continue the voyage. He exhorted: “Burn your ships! Calm seas do not make for good sailors. Get out of your comfort zone and get comfortable with being uncomfortable.”


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept